Email Artikel ini 
Review: Sistem Penghantaran Obat Tertarget Epidermal Growth Factor Receptor pada Kanker Payudara
Abstrak
Kanker payudara menjadi salah satu penyebab utama kematian akibat kanker pada populasi wanita di dunia. Tingginya kematian yang terjadi berkorelasi dengan rendahnya efektivitas terapi yang diberikan. Melalui sistem penghantaran obat tertarget pada pengobatan kanker payudara menjadi alternatif baru dalam upaya peningkatan efektivitas terapi. Tinjauan sistematis ini bertujuan untuk menelusuri dan mengumpulkan berbagai data yang memuat potensi terkait perkembangan sistem penghantaran obat tertarget EGFR pada pengobatan kanker payudara. Penelusuran data dilakukan menggunakan kata kunci "((Breast Cancer) AND (Targeted Drug Delivery) AND (Epidermal Growth Factor Receptor OR EGFR)) NOT Review” pada basis data Scopus, ScienceDirect, dan PubMed Central. Berdasarkan telaah artikel, diketahui bahwa sistem penghantaran tertarget EGFR pada kanker payudara saat ini dikembangkan dalam bentuk konjugat antibodi-obat, nanopartikel aptamer-protamine-siRNA (APR), konjugat affibodi-hibrid DNA, antibodi biparatopik-bispesifik, konjugat sel T-Designed Ankyrin Repeat Proteins (DAR-Pins), konjugat multikomponen dalam bentuk dendrimer PAMAM, dan chimera bivalen aptamer-siRNA. Selain itu, target spesifik yang banyak digunakan dalam metode terkini meliputi EGFR natural, HER2, HER3, asam folat, serta gen ErbB3. Perkembangan ini menunjukkan besarnya potensi terapi berbasis penghantaran tertarget EGFR dalam pengobatan kanker payudara.
Kata Kunci
Teks Lengkap:
PDFReferensi
Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017 Oct 2;50(1):33.
WHO. Cancer Country Profile. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
Moo T-A, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018 Jul;13(3):339–54.
Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer (Auckl). 2015 Sep 27;9(Suppl 2):17–34.
Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;1–9.
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012/10/17. 2012 Nov;136(2):331–45.
Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018 Aug 31;1(1):13–7.
Jin MH, Nam A-R, Park JE, Bang J-H, Bang Y-J, Oh D-Y. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. Mol Cancer Ther. 2017 Jun;16(6):1145–54.
Iqbal J, Anwar F, Afridi S. Targeted Drug Delivery Systems and Their Therapeutic Applications in Cancer and Immune Pathological Conditions. Infect Disord Drug Targets. 2017;17(3):149–59.
Si Y, Xu Y, Guan J, Chen K, Kim S, Yang ES, et al. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. Eng Life Sci. 2020 Oct 7;21(1–2):37–44.
Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016/06/22. 2016 Jul;107(7):1039–46.
Kumar A, Lale S V, Aji Alex MR, Choudhary V, Koul V. Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: In-vitro and in-vivo studies. Colloids Surfaces B Biointerfaces. 2017;149:369–78.
Ito K, Mitsunaga M, Nishimura T, Saruta M, Iwamoto T, Kobayashi H, et al. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer. Bioconjug Chem. 2017 May;28(5):1458–69.
Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, et al. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Front Oncol. 2021 Apr 23;11:638482.
Xu X, Li L, Li X, Tao D, Zhang P, Gong J. Aptamer-protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells. Int J Pharm. 2020;590:119963.
Zhang C, Zhang F, Han M, Wang X, Du J, Zhang H, et al. Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer. Sci Rep. 2020 Dec 16;10(1):22015.
Liu J, Wu X, Lin L, Pan H, Wang Y, Li Y, et al. Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities. Mol Ther oncolytics. 2019 Apr 2;14:66–73.
Siegler E, Li S, Kim YJ, Wang P. Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells. Hum Gene Ther. 2017/06/22. 2017 Sep;28(9):726–36.
Marcinkowska M, Stanczyk M, Janaszewska A, Sobierajska E, Chworos A, Klajnert-Maculewicz B. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy. Pharm Res. 2019 Sep 3;36(11):154.
Xue L, Maihle NJ, Yu X, Tang S-C, Liu HY. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth. Mol Pharm. 2018/10/01. 2018 Nov 5;15(11):4801–13.
Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-Drug Conjugates: The New Frontier of Chemotherapy. Int J Mol Sci. 2020 Jul 31;21(15):5510.
Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals (Basel). 2018 Apr 9;11(2):32.
Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. J Natl Cancer Inst. 2019 Jun;111(6):538–49.
Diamantis N, Banerji U. Antibody-drug conjugates--an emerging class of cancer treatment. Br J Cancer. 2016/01/07. 2016 Feb 16;114(4):362–7.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov;367(19):1783–91.
Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res. 2017/12/26. 2017 Dec;52(4):243–53.
Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019/07/23. 2019 Aug 20;52(8):2332–9.
Ogitani Y, Abe Y, Iguchi T, Yamaguchi J, Terauchi T, Kitamura M, et al. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorg Med Chem Lett. 2016 Oct;26(20):5069–72.
Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M. Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open. 2012 Jan 12;2(1):e000653–e000653.
Bae SY, La Choi Y, Kim S, Kim M, Kim J, Jung SP, et al. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat. 2013 Jun;139(3):741–50.
Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010 Mar 1;116(5):1234–42.
Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet (London, England). 2019 Aug;394(10200):793–804.
Zhang Y, Lai BS, Juhas M. Recent Advances in Aptamer Discovery and Applications. Molecules. 2019 Mar 7;24(5):941.
Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181–202.
Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, et al. Molecular Mechanisms and Biological Functions of siRNA. Int J Biomed Sci. 2017 Jun;13(2):48–57.
Itani R, Al Faraj A. siRNA Conjugated Nanoparticles-A Next Generation Strategy to Treat Lung Cancer. Int J Mol Sci. 2019 Dec 3;20(23):6088.
de Vries JW, Zhang F, Herrmann A. Drug delivery systems based on nucleic acid nanostructures. J Control Release. 2013 Dec;172(2):467–83.
Kong F-Y, Zhang J-W, Li R-F, Wang Z-X, Wang W-J, Wang W. Unique Roles of Gold Nanoparticles in Drug Delivery, Targeting and Imaging Applications. Molecules. 2017 Aug 31;22(9):1445.
Feldwisch J, Tolmachev V. Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol. 2012;899:103–26.
Akiba H, Takayanagi K, Kusano-Arai O, Iwanari H, Hamakubo T, Tsumoto K. Generation of biparatopic antibody through two-step targeting of fragment antibodies on antigen using SpyTag and SpyCatcher. Biotechnol reports (Amsterdam, Netherlands). 2020 Jan 11;25:e00418–e00418.
Yang H, Parkhouse RME, Wileman T. Monoclonal antibodies that identify the CD3 molecules expressed specifically at the surface of porcine gammadelta-T cells. Immunology. 2005 Jun;115(2):189–96.
Ames E, Hallett WHD, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol. 2009 Mar;155(3):504–13.
Kulemzin S V, Kuznetsova V V, Mamonkin M, Taranin A V, Gorchakov AA. Engineering Chimeric Antigen Receptors. Acta Naturae. 2017;9(1):6–14.
Smithwick E, Stewart MW. Designed Ankyrin Repeat Proteins: A Look at their Evolving Use in Medicine with a Focus on the Treatment of Chorioretinal Vascular Disorders. Antiinflamm Antiallergy Agents Med Chem. 2017;16(1):33–45.
Abedi-Gaballu F, Dehghan G, Ghaffari M, Yekta R, Abbaspour-Ravasjani S, Baradaran B, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater today. 2018/05/29. 2018 Sep;12:177–90.
Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014 Jul;6(3):139–50.
Chis AA, Dobrea C, Morgovan C, Arseniu AM, Rus LL, Butuca A, et al. Applications and Limitations of Dendrimers in Biomedicine. Molecules. 2020 Sep 1;25(17):3982.
Araújo RV de, Santos S da S, Igne Ferreira E, Giarolla J. New Advances in General Biomedical Applications of PAMAM Dendrimers. Molecules. 2018 Nov 2;23(11):2849.
Kavyani S, Amjad-Iranagh S, Modarress H. Aqueous poly(amidoamine) dendrimer G3 and G4 generations with several interior cores at pHs 5 and 7: a molecular dynamics simulation study. J Phys Chem B. 2014 Mar;118(12):3257–66.
De Los Angeles A, Pho N, Redmond Jr DE. Generating Human Organs via Interspecies Chimera Formation: Advances and Barriers. Yale J Biol Med. 2018 Sep 21;91(3):333–42.
Refbacks
- Saat ini tidak ada refbacks.
